Laboratory Co. of America Holdings (NYSE:LH) Shares Acquired by Wilmington Savings Fund Society FSB

Wilmington Savings Fund Society FSB boosted its holdings in Laboratory Co. of America Holdings (NYSE:LH) by 34.6% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 25,847 shares of the medical research company’s stock after buying an additional 6,651 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Laboratory Co. of America were worth $5,776,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Dynamic Advisor Solutions LLC lifted its holdings in shares of Laboratory Co. of America by 6.0% during the second quarter. Dynamic Advisor Solutions LLC now owns 1,153 shares of the medical research company’s stock valued at $235,000 after purchasing an additional 65 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Laboratory Co. of America by 3.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 17,156 shares of the medical research company’s stock worth $3,491,000 after buying an additional 575 shares during the period. Great Valley Advisor Group Inc. purchased a new position in shares of Laboratory Co. of America in the second quarter worth approximately $473,000. Envestnet Portfolio Solutions Inc. raised its holdings in shares of Laboratory Co. of America by 13.1% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 8,955 shares of the medical research company’s stock valued at $1,823,000 after acquiring an additional 1,038 shares during the period. Finally, Swedbank AB lifted its position in shares of Laboratory Co. of America by 2.9% in the 2nd quarter. Swedbank AB now owns 50,795 shares of the medical research company’s stock valued at $10,337,000 after acquiring an additional 1,450 shares in the last quarter. Institutional investors own 95.94% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on LH shares. Jefferies Financial Group reiterated a “buy” rating and set a $275.00 price objective (up from $265.00) on shares of Laboratory Co. of America in a research report on Tuesday. Evercore ISI lowered their price target on Laboratory Co. of America from $250.00 to $240.00 and set an “in-line” rating on the stock in a report on Tuesday, September 24th. Robert W. Baird raised their price objective on Laboratory Co. of America from $282.00 to $289.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Hsbc Global Res raised Laboratory Co. of America from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Barclays increased their price target on shares of Laboratory Co. of America from $234.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Friday, October 25th. Five analysts have rated the stock with a hold rating, ten have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $256.75.

Insiders Place Their Bets

In related news, EVP Glenn A. Eisenberg sold 11,711 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $240.43, for a total value of $2,815,675.73. Following the sale, the executive vice president now owns 31,289 shares of the company’s stock, valued at $7,522,814.27. The trade was a 27.23 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Kerrii B. Anderson sold 1,000 shares of Laboratory Co. of America stock in a transaction on Thursday, October 24th. The shares were sold at an average price of $230.00, for a total value of $230,000.00. Following the transaction, the director now directly owns 13,722 shares of the company’s stock, valued at approximately $3,156,060. The trade was a 6.79 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,572 shares of company stock valued at $5,910,209 over the last 90 days. 0.85% of the stock is currently owned by company insiders.

Laboratory Co. of America Stock Performance

LH stock opened at $231.84 on Friday. The firm has a 50 day moving average of $230.40 and a two-hundred day moving average of $219.97. Laboratory Co. of America Holdings has a 12 month low of $191.97 and a 12 month high of $247.99. The company has a market capitalization of $19.39 billion, a price-to-earnings ratio of 44.84, a P/E/G ratio of 1.89 and a beta of 1.05. The company has a quick ratio of 1.30, a current ratio of 1.44 and a debt-to-equity ratio of 0.66.

Laboratory Co. of America (NYSE:LH) last released its quarterly earnings data on Thursday, October 24th. The medical research company reported $3.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.48 by $0.02. Laboratory Co. of America had a net margin of 3.43% and a return on equity of 15.27%. The business had revenue of $3.28 billion during the quarter, compared to analyst estimates of $3.26 billion. During the same quarter in the previous year, the business earned $3.38 EPS. Laboratory Co. of America’s quarterly revenue was up 7.4% compared to the same quarter last year. As a group, equities analysts anticipate that Laboratory Co. of America Holdings will post 14.52 EPS for the current fiscal year.

Laboratory Co. of America Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Tuesday, November 26th will be issued a $0.72 dividend. The ex-dividend date is Tuesday, November 26th. This represents a $2.88 annualized dividend and a yield of 1.24%. Laboratory Co. of America’s dividend payout ratio (DPR) is currently 55.71%.

About Laboratory Co. of America

Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.